Ask AI
ProCE Banner Activity

CE / CME

Mastering the Evolving Treatment Paradigm in SCLC: Expert Case Discussions to Aid Integration of Immunotherapy and Novel Targeted Therapies

Video

In this certified on-demand webcast, experts discuss the evolving treatment landscape for small cell lung cancer (SCLC), emphasizing molecular subtyping, novel therapeutic targets, and the integration of emerging biomarkers. The discussion highlights advances in immunotherapy, antibody–drug conjugates, and targeted therapies aimed at improving patient outcomes.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

ABIM MOC: maximum of 1.50 Medical Knowledge MOC points

Released: June 23, 2025

Expiration: December 22, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Amgen, Daiichi Sankyo, Inc., Jazz Pharmaceuticals, Inc. and Merck Sharp & Dohme LLC.

Amgen

Daiichi Sankyo, Inc.

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme, LLC

Target Audience

This educational activity is intended for medical oncologists and other healthcare professionals who care for patients with SCLC. 

Program Learning Goal

This activity's goal is to improve the knowledge and competence of learners in the optimal management of patients with SCLC.

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Apply current evidence and guideline recommendations to effectively incorporate immunotherapy into individualized treatment plans for patients with LS-SCLC

  • Select and sequence therapy for patients with ES-SCLC considering immunotherapy and recently approved targeted and cytotoxic therapies​

  • Employ comprehensive strategies to prevent, monitor, and address TRAEs related to immunotherapy and novel treatments for SCLC​

  • Evaluate the latest evidence on investigational agents currently in testing for SCLC

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Melissa L. Johnson, MD: researcher (paid to institution): Adaptimmune, Amgen, ArriVent, AstraZeneca, Bayer, Black Diamond, BlossomHill, Boehringer Ingelheim, Boundless Bio, Bristol Myers Squibb, Carisma, Conjupro Biotherapeutics, Corvus, D3 Bio, Daiichi Sankyo, Erasca, Exelixis, Genentech/Roche, Genmab, Genocea, Harpoon, Helsinn Healthcare SA, IDEAYA, IGM, Immuneering, Immunitas, Immunocore, Incyte, Janssen, Lilly, Lockbody, Loxo Oncology, Merck, Merus, Mirati, Modex, Mythic, NeoImmune Tech, Neovia Oncology, NextPoint, Novartis, Nuvalent, OncoC4, Palleon, Pfizer, Pierre Fabre, PMV Pharmaceuticals, Prelude, Puma Biotechnology, RasCal, Regeneron, Revolution Medicines, Ribon, Shattuck Labs, Shanghai Junshi Biosciences, Silicon, Summit, Systimmune, Taiho Oncology, TCR2, Tempest, TheRas, Tizona, Vividion, Zymeworks; consultant/advisor/speaker (paid to institution): AbbVie, Alentis, Amgen, Arcus Biosciences, AstraZeneca, BeOne Medicines, Biohaven, Boehringer Ingelheim, Bristol Myers Squibb, D3 Bio Limited, Daiichi Sankyo, Fate, Genentech/Roche, Gilead Sciences, GlaxoSmithKline, Hookipa Biotech, Janssen, Jazz, Lilly, Merck, Mirati, ModeX, Normunity, Novartis, Novocure, Pfizer, Regeneron, Revolution Medicines, Takeda, Zai Laboratory.

Ticiana Leal, MD: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, Black Diamond, Boehringer Ingelheim, Bristol Myers Squibb, Catalyst, Genentech, Gilead, Jazz, Johnson & Johnson, Novocure, OncoC4, Pfizer, Regeneron, Roche, Summit Therapeutics, Synthekine; researcher (paid to institution): AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Nuvalent, Prelude, Synthekine.

Mark A. Socinski, MD: consultant/advisor/speaker: AstraZeneca, BeiGene, Bristol Myers Squibb, Genentech, Guardant, Janssen, Jazz, Merck, Spectrum, Summit; researcher: AstraZeneca, BeiGene, Enliven, Spectrum.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 23, 2025, through December 22, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.

  2. Read the target audience, learning objectives, and faculty disclosures.

  3. View and study the content in its entirety.

  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/67167f3d10da3.png

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through CCO's Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Clinical Care Options, LLC permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

CME Passport

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/662be69741e7b.png

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.